Statins and lipid-lowering strategies in PD

Contributions to Nephrology

Volumn 178, Issue , 2012, Pages 106-110

  Heimbürger, Olof ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862136904     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000337828     Document Type: Article

References (17)

1. Prichard SS: Management of hyperlipidemia in patients on peritoneal dialysis: current approaches. Kidney Int 2006;(suppl 103):S115- S117.
2. Epstein M, Vaziri ND: Statins in the management of dyslipidemia associated with chronic kidney disease. Nat Rev Nephrol 2012 Feb 21. doi: 10.1038/nrneph.2012.33. [Epub ahead of print].
3. Heimbürger O, Stenvinkel P, Berglund L, Tranoeus A, Lindholm B: Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Nephron 1996;72:135- 144.
4. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793- 808.
5. Liu Y, Coresh J, Eustace JA, Longnecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients. Role of inflammation and malnutrition. JAMA 2004;291:451- 459.
6. Navaneethan SD, Nigwekar SU, Perkovic V, Johnson DW, Craig JC, Strippoli GF: HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev 2009;2:CD004289.
7. Wanner C, Krane V, März W, Olschewski M, Mann J, Ruf G, Ritz E, German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238- 248.
8. März W, Genser B, Drechsler C, Krane V, Grammer TB, Ritz E, Stojakovic T, Scharnagl H, Winkler K, Holme I, Holdaas H, Wanner C, German Diabetes and Dialysis Study Investigators: Atorvastatin and lowdensity lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 2011;6:1316- 1325.
9. Fellström BC, Jardine AG, Schmieder RE, et al: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395- 1407.
10. Baigent C, Landray MJ, Reith C, et al: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo- controlled trial. Lancet 2011;377:2181- 2192.
11. Goldfarb-Rumyantzev AS, Habib AN, Baird BC, Barenbaum LL, Cheung AK: The association of lipid- modifying medications with mortality in patients on long-term peritoneal dialysis. Am J Kidney Dis 2007;50:791- 802.
12. Lee JE, Oh K- H, Choi KH, Kim SB, Kim Y-S, Do J-Y, Kim Y-L, Kim DJ: Statin therapy is associated with improved survival in incident peritoneal dialysis patients: propensitymatched comparison. Nephrol Dial Transplant 2011;26:4090- 4094.
13. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Perrone Filardi P, Riccardi G, Storey RF, Wood D, ESC Committee for Practice Guidelines 2008- 2010 and 2010- 2012 Committees: ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217(suppl 1):S1- S44.
14. Heimburger O: Lipid disorders, statins and the peritoneal membrane. Contrib Nephrol. Basel, Karger, 2009, vol 163, pp 177- 182.
15. Paniagua R, Ventura MD, Avila-Díaz M, Cisneros A, Vicenté-Martínez M, Furlong MD, García-González Z, Villanueva D, Orihuela O, Prado-Uribe MD, Alcántara G, Amato D: Icodextrin improves metabolic and fluid management in high and highaverage transport diabetic patients. Perit Dial Int 2009;29:422- 432.
16. Hassan KS, Hassan SK, Hijazi EG, Khazim KO: Effects of omega- 3 on lipid profile and inflammation markers in peritoneal dialysis patients. Ren Fail 2010;32:1031- 1035.
17. Tabibi H, Imani H, Hedayati M, Atabak S, Rahmani L: Effects of soy consumption on serum lipids and apoproteins in peritoneal dialysis patients: a randomized controlled trial. Perit Dial Int 2010;30:611- 618.